Clinical Trials Browser

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00021216 2015-04-15

Bortezomib in Treating Children With Advanced Solid Tumors

Phase 1 Completed

36 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT01240538 2014-05-13

Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors

Phase 1 Completed

26 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00880282 2014-04-29

Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

Phase 1 Completed

39 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT01141244 2014-04-10

Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase 1 Completed

72 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00006095 2014-02-21

Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy

Phase 1 Completed

20 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00006463 2014-02-21

Ecteinascidin 743 in Treating Children With Refractory Solid Tumors

Phase 1 Completed

13 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00070473 2014-02-20

Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors

Phase 1 Completed

33 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00436761 2013-12-18

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Phase 1 Unknown

20 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00004919 2013-07-02

Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy

Phase 1 Completed

30 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00016861 2013-06-26

Irinotecan in Treating Children With Refractory or Progressive Solid Tumors

Phase 1 Completed

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00085111 2013-06-05

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Phase 1 Completed

24 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00024284 2013-04-05

Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

Phase 1 Completed

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00003288 2013-02-05

Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors

Phase 1 Completed

12 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00003370 2013-02-05

Irofulven in Treating Children With Recurrent or Refractory Solid Tumors

Phase 1 Completed

12 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00005577 2013-02-05

Gemcitabine in Treating Children With Refractory Solid Tumors

Phase 1 Completed

30 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00040781 2013-01-23

Gefitinib in Treating Children With Refractory Solid Tumors

Phase 1 Completed

45 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00005844 2012-10-23

Oxaliplatin in Treating Children With Advanced Solid Tumors

Phase 1 Completed

26 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

Clinical Trials

AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors

Bortezomib in Treating Children With Advanced Solid Tumors

Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors

Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy

Ecteinascidin 743 in Treating Children With Refractory Solid Tumors

Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy

Irinotecan in Treating Children With Refractory or Progressive Solid Tumors

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors

Irofulven in Treating Children With Recurrent or Refractory Solid Tumors

Gemcitabine in Treating Children With Refractory Solid Tumors

Gefitinib in Treating Children With Refractory Solid Tumors

Oxaliplatin in Treating Children With Advanced Solid Tumors